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Crimean-Congo hemorrhagic fever (CCHF) is a highly 
contagious viral tick-borne disease with case-fatality rates 
as high as 50%. We describe a collaborative evaluation of 
the characteristics, performance, and on-site applicability of 
serologic and molecular assays for diagnosis of CCHF. We 
evaluated ELISA, immunofl uorescence, quantitative reverse 
transcription PCR, and low-density macroarray assays for 
detection of CCHF virus using precharacterized archived 
patient serum samples. Compared with results of local, in-
house methods, test sensitivities were 87.8%–93.9% for 
IgM serology, 80.4%–86.1% for IgG serology, and 79.6%–
83.3% for genome detection. Specifi city was excellent 
for all assays; molecular test results were infl uenced by 
patient country of origin. Our fi ndings demonstrate that 
well-characterized, reliable tools are available for CCHF 
diagnosis and surveillance. The on-site use of such assays 
by health laboratories would greatly diminish the time, costs, 
and risks posed by the handling, packaging, and shipping of 
highly infectious biologic material.
Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne zoonotic disease caused by a virus (CCHFV) 
belonging to the Nairovirus genus (1). The disease is 
asymptomatic in infected animals but can develop into 
severe illness in humans, with case-fatality rates as high 
as 50% in some outbreaks (2,3). The incubation period is 
typically 3–7 days, with sudden onset of myalgia, headache, 
and fever that can develop into a severe hemorrhagic 
syndrome (4,5). CCHFV is transmitted by tick bite (from 
mainly Hyalomma spp. ticks) or by contact with blood or 
tissues from infected livestock or patients with CCHF (2,6).
Sporadic cases of CCHF and community and 
nosocomial outbreaks have been increasingly reported, and 
the disease’s geographic distribution is the most extensive 
among tick-borne diseases. Currently, CCHFV is enzootic 
in southeastern Europe (Bulgaria, Albania, Kosovo, and 
Greece), southern Russia, and several countries in the 
Middle East, Africa, and Asia (7–9). Given the abundance 
of vectors, potential hosts, favorable climate and ecology, 
and intensifi ed human travel, emergence and rapid 
establishment of new CCHF foci in other countries are 
substantial risks (10). Emergence or reemergence of CCHF 
poses a serious public health threat because it is highly 
contagious and highly lethal, has the potential to cause 
nosocomial infection, and is diffi cult to treat, prevent, 
and control. In addition to enhanced surveillance and 
development of therapeutics, access to early, sensitive, and 
specifi c laboratory diagnosis is a key factor in increasing 
preparedness in Europe and other countries at risk (11–13).
Although viral isolation is the standard for CCHF 
diagnosis, because it has to be done in high-containment 
biosafety level 4 facilities, the number of laboratories that 
can perform this technique is limited. Moreover, because 
cell cultures lack sensitivity and usually only detect the 
relatively high viremia level encountered during the fi rst 
5 days of illness, viral isolation is not without error or 
uncertainty. As a consequence, reference laboratories 
have been using the best available practicable methods 
to determine the presence or absence of infection (11). 
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Diagnostic Assays for CCHF
These methods include conventional and real-time 
quantitative reverse transcription PCR (RT-PCR and 
qRT-PCR) for detection of the viral genome (14–18) and 
indirect immunofl uorescence assays (IFAs) or ELISAs for 
detection of specifi c IgM and IgG antibodies (19–22). No 
consensus on the most effi cient molecular and serologic 
testing method has been reached.
In this context, a working group of experts from 
reference laboratories was constituted under the initiative 
of the European Network for Diagnostics of Imported 
Viral Diseases to take part in a multicenter study of CCHF 
diagnostic tests. The aim of this study was to evaluate and 
compare the performance of, and review the operational 
characteristics of, available CCHF diagnostic tests by using 
panels of well-characterized, archived serum samples from 
patients from geographically diverse settings.
Materials and Methods
Study Participants and Diagnostic Tools
Experts from 5 institutions participated in this study: 
Bundeswehr Institute of Microbiology, Munich, Germany; 
Department of Microbiology, Aristotle University of 
Thessaloniki, Thessaloniki, Greece; Center for Vectors and 
Infectious Diseases Research, National Institute of Health, 
Águas de Moura, Portugal; Institute of Microbiology and 
Immunology, Medical Faculty, Ljubljana, Slovenia; and 
Center for Microbiological Preparedness, Swedish Institute 
for Infectious Disease Control, Solna, Sweden. Diagnostic 
methods that could be performed in standard laboratory 
facilities were selected on the basis of a systematic review 
of the literature and the experiences of the members of the 
working group. During April 2010, an extensive search of 
available CCHF diagnostic tools was performed by using 
both generic (Google) and scientifi c (PubMed) Internet-
based search engines. To meet the selection criteria, assays 
had to be commercially available or in the prerelease phase 
at the time of our assessment (or have quality assessed 
reagents and well-defi ned protocols for noncommercial 
assays); yield early and rapid results (within 5 hours); 
not require the purchase of specifi c equipment; and 
have demonstrated suffi cient scope to detect diverse 
CCHFV variants or antibodies. The reporting of results 
was conducted according to Standards for Reporting of 
Diagnostic Accuracy criteria (www.stard-statement.org; 
online Technical Appendix Table 1, wwwnc.cdc.gov/EID/
pdfs/12-0710-Techapp.pdf).
Patient Status Defi nition and Samples
Because no reference test for CCHV is universally 
accepted, patients with clinically suspected CCHF were 
confi rmed on the basis of results of serologic and molecular 
diagnostic tests that were in use in the CCHF reference 
laboratories at the time of the study (Table 1). These 
cases were defi ned by the either positive rule: detection 
of CCHFV genome or CCHFV-specifi c IgM, IgG, or 
both, during either the acute or convalescent phase of the 
disease. Each participant in the working group contributed 
a panel of archived serum samples that had tested positive 
for CCHFV by IgM, IgG, or both, and a panel of archived 
serum RNA extracts from which CCHFV genome had 
been detected; samples were collected from patients with 
laboratory-confi rmed CCHF infection. Negative controls 
were samples from healthy persons who originated from 
disease-endemic or at-risk areas (e.g., blood donors) and 
samples from febrile patients with a diagnosis of 1 of the 
conditions that can produce symptoms similar to those 
of CCHFV infection (e.g., hemorrhagic fever with renal 
syndrome, leptospirosis, West Nile fever, chikungunya). 
All samples were included in the study with the consent of 
the patients.
Assay Methodology and Data Collection
Tests were performed according to the manufacturers’ 
instructions or according to validated protocols provided 
by the developer. Working group members tested the 
selected assays in duplicate on their respective sample 
panels within their facilities. Results of qualitative assays 
(IFAs and low-cost, low-density [LCD] arrays) were read 
by 2 independent readers. Results were collected at the end 
of each testing session by using a standard report datasheet 
and combined into a fi nal database.
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Table 1. Reference methods used by the reference laboratories that participated in evaluation of serologic and molecular assays for 
diagnosis of CCHF 
Laboratory Reference IgM serologic tests Reference IgG serologic tests Reference molecular tests 
1 In-house IFA (CCHFV-infected cells) In-house IFA (CCHFV-infected cells) Nested RT-PCR (23) and 
qRT-PCR (24)
2 In-house IgM capture ELISA (CCHFV 
strain IbAr10200 antigen) 
In-house sandwich ELISA (CCHFV strain 
IbAr10200 antigen) 
Nested RT-PCR (25) and 
qRT-PCR (17)
3 In-house IFA (CCHFV strain ArD39554 
infected cells) 
In-house IFA (CCHF strain ArD39554 
infected cells) 
qRT-PCR (18)
4 In-house IFA (CCHFV infected cells) In-house IFA (CCHF infected cells) qRT-PCR (18)
5 Testing performed by external reference 
laboratory 
Testing performed by external reference 
laboratory 
qRT-PCR (18)
*CCHF, Crimean-Congo hemorrhagic fever; IFA, immunofluorescence assay; CCHFV, CCHF virus; RT-PCR, reverse transcription PCR; qRT-PCR, 
quantitative RT-PCR. 
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Data Analysis
Results obtained for each selected diagnostic tool were 
compared in a 2×2 table with results from the reference 
in-house diagnostic to estimate indices of sensitivity, 
specifi city, and corresponding 95% CIs. In addition, test 
results were compared with the results of a composite 
reference standard (positive if detection of specifi c 
CCHFV genome or specifi c CCHF IgM or IgG antibodies 
by in-house reference methods; negative otherwise) 
to confi rm the specifi city estimates and corresponding 
95% CIs. Statistical analysis was performed in STATA/
SE version 12.0 software (StataCorp, College Station, 
TX, USA). CIs were calculated by using binomial exact 
methods. A univariate analysis was conducted by using 
the Fisher exact test to identify factors infl uencing test 
sensitivity (i.e., patient country of origin, severity of 
disease, number of days after illness onset that sample 
was collected, and sample storage time before testing); 
p<0.05 was considered signifi cant. A multinomial exact 
logistic regression analysis was performed to identify 
independent factors infl uencing sensitivity, including 
all variables associated with sensitivity in the univariate 
analysis (p<0.1). Data on operational characteristics 
of each test (i.e., ease-of-use, level of staff training 
required, time, ease of interpretation) were gathered 
through a questionnaire. Tests were scored on operational 
characteristics.
Results
Selected Diagnostic Methods
Six diagnostic assays met the criteria for inclusion in 
the study. For specifi c CCHF serodiagnosis, a commercial 
IgM and IgG ELISA (Vector-Best, Novosibirsk, Russia) 
and a commercial IgM and IgG IFA (Euroimmun, 
Luebeck, Germany) were selected. For detection of 
the CCHFV genome, a commercial real-time RT-PCR 
(Altona-Diagnostics, Hamburg, Germany) and a low-cost, 
low-density macroarray (26) were used. Characteristics 
of the selected tests are shown in Table 2. After selection, 
assays were purchased directly from the manufacturers 
and shipped according to their instructions to the working 
group members by express delivery.
Characteristics of Study Population 
and Sample Panels
The serum panel constituted for the evaluation of the 
serologic tests consisted of 66 stored serum samples from 
acute-phase CCHF patients (those who recovered or died) 
and patients with confi rmed CCHF diagnosis who had 
an early recovery; 32 samples from febrile patients who 
had symptoms compatible with CCHFV infection; and 
41 samples from healthy persons. Molecular tests were 
evaluated by using a panel of RNA extracts from acute-
phase patient serum samples: 54 samples from patients with 
confi rmed CCHF diagnosis, 16 samples from febrile patients 
who had symptoms compatible with CCHFV infection, 
and 5 samples from healthy persons. Characteristics of 
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Table 2. Characteristics of selected assays compared in study of CCHF diagnostic tools 
Characteristics IgM ELISA IgG ELISA IgM IFA IgG IFA qRT-PCR LCD array 
Assay (manufacturer, 
location or reference) 
VectoCrimea-CHF ELISA 
(Vector-Best, Novosibirsk, 
Russia) 
Crimean-Congo Fever Mosaic 2 
IFA (Euroimmun, Luebeck, 
Germany) 
RealStar CCHFV 
RT-PCR Kit 1.2 
(Altona-Diagnostics, 
Hamburg, Germany) 
CCHF2006 1.5 
LCD Kit (26)
Reference no. D-5054 D-5056 FI 279a-1010-
2M
FI 279a-1010-
2G
181203 NA
Target CCHFV-
specific IgM 
CCHFV-
specific IgG 
CCHFV-specific
IgM
CCHFV-
specific IgG 
CCHFV S segment CCHFV S 
segment
Shelf life, mo 9 9 18 18 12 Unknown 
Storage temperature, °C 2 to 8 2 to 8 2 to 8 2 to 8 15 to 25 2 to 8, 20 
Quoted accuracy, % 
 Sensitivity 100 100 97.2 89.5 Unknown 100
 Specificity 100 100 97.5 100 Unknown 100
Sample type Serum,
plasma
Serum,
plasma
Serum, plasma Serum, plasma RNA extract from 
serum or blood 
RNA extract 
from serum or 
blood
Sample volume, μL 10 10 5 5 10 10
Minimum kit format (no. 
reactions)
12 strips × 8 
tests (96) 
12 strips × 8 
tests (96) 
10 slides × 5 
tests (50) 
10 slides × 5 
tests (50) 
8 tubes × 12 tests 
(96) 
4 slides × 8 
tests (32) 
Price, Euros† 
 Per kit 139.2 139.2 326 326 1,200 Unknown 
 Per reaction 1.45 1.45 6.51 6.51 12.50 Unknown 
Estimated run time, min 175 175 70 70 58 175
*CCHFV, Crimean-Congo hemorrhagic fever virus; IFA, immunofluorescence assay; qRT-PCR, quantitative reverse transcription PCR; LCD, low-cost, 
low-density; NA, not applicable; S segment, small segment. 
†Does not include shipping costs. 
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the patient population and the sample panels are shown 
in Table 3. Confi rmed CCHF case-patients originated 
from Iran, Kosovo, Albania, Turkey, and sub-Saharan 
Africa; most had moderate CCHF. Patients with symptoms 
compatible with CCHF infection included patients who 
had a diagnosis of leptospirosis, chikungunya fever, 
hemorrhagic fever with renal syndrome (HFRS), Q fever, 
tularemia, brucellosis, and West Nile encephalitis. Serum 
samples were collected 5–49 days after onset of symptoms; 
RNA extracts were obtained from serum samples collected 
2–14 days after onset of symptoms. Storage time until 
testing ranged from 1 to 23 years for serum samples and 1 
to 4 years for RNA extracts.
Performances of Selected CCHF IgM Serology Assays
A total of 138 and 90 samples from the collected patient 
serum panels were tested for CCHFV-specifi c IgM by the 
Vector-Best ELISA and the Euroimmun IFA, respectively. 
Because of limited sample amounts, IFA could not be 
performed on all collected samples. When compared with 
the reference IgM serology tests, the sensitivity of the 
IgM ELISA ranged from 75.0% to 100.0% for different 
laboratories, with an overall sensitivity of 87.8% (95% 
CI 78.6%–96.9%). For the IgM IFA, sensitivity ranged 
from 75.0% to 100.0%, with an overall sensitivity of 
93.9% (95% CI 85.8%–100.0%). Overall specifi city was 
estimated to be 98.9% (95% CI 96.7%–100.0%) for the 
IgM ELISA and 100% for the IgM IFA (Table 4). When 
a composite reference standard (described in the Methods 
section) was used as reference, the observed specifi city was 
100% for both tests.
Performances of Selected CCHF IgG Serology Assays
A total of 137 and 92 samples from the collected patient 
serum panel were tested for CCHFV-specifi c IgG by the 
Vector-Best ELISA and the Euroimmun IFA, respectively. 
When compared with the reference IgG serology tests, the 
estimated sensitivity for the IgG ELISA ranged from 75.0% 
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Table 3. Patient characteristics and sample storage information for samples tested for CCHFV 
Characteristics
Sample panel 1, serology, no. (%) Sample panel 2, genome detection, no. (%) 
CCHFV positive, n = 
66
CCHFV negative, n = 
73
CCHFV positive, n = 
54
CCHFV negative, n = 
21
Conditions
 CCHF 66 (100.0) 0 54 (100.0) 0
 Brucellosis 0 2 (2.7) 0 2 (9.5) 
 Chikungunya 0 1 (1.4) 0 1 (4.8) 
 HFRS 0 13 (17.8) 0 7 (33.3) 
 Leptospirosis 0 13 (17.8) 0 3 (14.3) 
 Q fever 0 1 (1.4) 0 1 (4.8) 
 Tularemia 0 1 (1.4) 0 1 (4.8) 
 West Nile fever 0 1 (1.4) 0 1 (4.8) 
 Healthy or non-CCHF 0 41 (56.2) 0 5 (23.8) 
Patient country of origin 
 Albania 9 (13.6) 0 8 (14.8) 0
 Germany 0 23 (31.5) 0 7 (33.3) 
 Greece 0 9 (12.3) 0 9 (42.9) 
 Iran 32 (48.5) 0 31 (57.4) 0
 Kosovo 21 (31.8) 20 (27.4) 7 (13.0) 4 (19.0) 
 Portugal 0 20 (27.4) 0 0
 Sub-Saharan Africa 4 (6.1) 0 0 0
 Turkey 0 1 (1.4) 8 (14.8) 1 (4.8) 
CCHF disease severity 
 Moderate 49 (74.2) 0 37 (68.5) 0
 Severe 11 (16.7) 0 2 (3.7) 0
 Fatal 3 (4.5) 0 6 (11.1) 0
 Asymptomatic 3 (4.5) 0 7 (13.0) 0
 Unknown 0 0 2 (3.7) 0
Length of illness, d 
 <15 d 46 (69.7) 0 43 (79.6) 0
t15 d 12 (18.2) 0 0 0
 Asymptomatic 3 (4.5) 0 7 (13.0) 0
 Unknown 5 (7.6) 0 4 (7.4) 0
Sample storage time, y 
 <10 49 (74.2) 64 (87.7) 54 (100.0) 10 (47.6) 
t10 17 (25.8) 0 0 2 (9.5) 
 Unknown 0 9 (12.3) 0 9 (42.9) 
Sample storage temperature, °C 
80 34 (51.5) 49 (67.1) 9 (16.7) 4 (19.1) 
70 32 (48.5) 0 45 (83.3) 9 (42.9) 
20 0 24 (32.9) 0 8 (38.1) 
*CCHF, Crimean-Congo hemorrhagic fever; CCHFV, CCHF virus; HFRS, hemorrhagic fever with renal syndrome. 
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to 100.0%, with an overall sensitivity of 80.4% (95% 
CI 69.5%–91.3%). For the IgG IFA, sensitivity ranged 
from 40.0% to 100.0%, with an overall sensitivity of 86.1% 
(95% CI 74.8%–97.4%). Specifi city was estimated to be 
100% for both assays (Table 4).
Performances of Selected CCHF Molecular Assays
A total of 71 and 70 samples, respectively, from 
the collected panel of serum RNA extracts were tested 
for the presence of the CCHF genome by the Altona-
Diagnostics CCHFV qRT-PCR and the CCHF LCD array. 
When compared with the results of the reference genome 
detection methods, sensitivity ranged from 42.9% to 100%, 
with an overall sensitivity of 79.6% (95% CI 68.3%–
90.9%) for the qRT-PCR and from 25.0% to 100% with 
an overall sensitivity of 83.3% (95% CI 72.8%–95.5%) for 
the LCD array. Both assays demonstrated a specifi city of 
95.5% (95% CI 90.6%–100%) (Table 4), which increased 
to 100% when the results of a composite reference standard 
were used as reference.
Factors Infl uencing Diagnostic Sensitivity
The infl uence of several patient and sample 
characteristics on the sensitivity of the selected assays 
was analyzed by univariate analysis (online Technical 
Appendix Table 2). The country of origin of the patient was 
found to be signifi cantly associated with the sensitivity of 
the IgG IFA (p = 0.02), the qRT-PCR (p<0.001), and the 
LCD array (p = 0.02). However, after multivariate analysis, 
this association only remained signifi cant for the qRT-PCR 
assay (p<0.001). In particular, the qRT-PCR was found to 
be less sensitive for samples from patients originating from 
Turkey (adjusted odds ratio [OR] 0.04, 95% CI 0.00–0.87) 
and from Albania (adjusted OR 0.02, 95% CI 0.00–0.16).
Operational Characteristics of the CCHF Diagnostics
Scores for operational characteristics are summarized 
in Table 5. The ELISA test obtained a higher overall score 
(8.5/10) compared with the IFA (6.7/10). The IFA scored 
lowest in the ease of interpretation of results (1.3/2) and in 
the requirement for specifi c technical training (0.3/1). The 
observed scores for molecular tests were within the same 
range (6.0–6.3/10). Both molecular assays demonstrated 
low scores for technical complexity (1.3–1.5/2) and training 
requirements for equipment and technique (0.3–0.5/1).
Discussion
A number of published studies have described major 
epidemics, community and nosocomial outbreaks, and the 
ecology of CCHF (4,7,8,27–30). These reports have shown 
that a distinct epidemiologic situation can arise in regions 
where the virus is endemic but also that new foci can 
emerge (10,31). The World Health Organization has listed 
CCHF among the emerging diseases for which control and 
prevention measures should be renewed and intensifi ed 
(13,32). In addition, an assessment of the importance 
and magnitude of vector-borne diseases initiated by the 
European Centre for Disease Prevention and Control 
identifi ed CCHF as a priority disease for the European 
Union (33).
A strong laboratory capacity, in particular standardized 
approaches for diagnostic methods and assay validation, 
has been identifi ed as a short-term priority in CCHF-
endemic areas and regions where CCHFV could be 
expected to circulate (11,12). The aim of this study was 
to identify and evaluate easily available, simple-to-perform 
CCHF diagnostic methods considered most suitable for 
widespread use in CCHF-endemic areas and countries at 
risk.
We assessed the performances of 2 commercially 
available IgM and IgG serologic tests, the Vector-Best 
CCHF ELISA and the Euroimmun CCHF IFA, and 2 
assays for viral genome detection, the Altona-diagnostics 
CCHF qRT-PCR and a CCHF LCD array. The IgM and IgG 
ELISAs showed a sensitivity of 88% and 80%, respectively, 
lower than the numbers given by the manufacturer. These 
assays were validated by the manufacturer by using serum 
panels from CCHF cases originating from southwestern 
Russia (S. Suchkov, pers. comm.). Therefore, lower 
sensitivity for certain serum samples tested in this study 
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Table 4. Overall performance of assays compared in study of CCHF diagnostic tools 
Parameter
IgM serology IgG serology Genome detection 
ELISA IFA ELISA IFA qRT-PCR LCD array 
No. samples tested 138 90 137 92 71 70
No. true positive 43 31 41 31 39 40
No. false negative 6 2 10 5 10 8
No. true negative 88 57 86 56 21 21
No. false positive 1 0 0 0 1 1
Sensitivity, % (95% CI) 87.8
(75.2–95.3) 
93.9
(79.8–99.3) 
80.4
(66.9–90.2) 
86.1
(70.5–95.3) 
79.6
(65.7–89.8) 
83.3
(69.8–92.5) 
Specificity, % (95% CI) 98.9
(93.9–100.0) 
100.0
(93.7–100.0)†
100.0
(95.8–100.0) 
100.0
(93.6–100.0) 
95.5
(77.2–99.9) 
95.5
(77.2–99.9) 
*CCHF, Crimean-Congo hemorrhagic fever; IFA, immunofluorescent assay; qRT-PCR, quantitative reverse transcription PCR; LCD, low-cost, low-
density. 
†One-sided 95% CI. 
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may refl ect antigenic variation among CCHFVs circulating 
in other countries.
Observed sensitivities of the IgM and IgG IFA were 
93.9% and 86.1%, respectively. Although these estimates 
are higher than those observed for the IgM and IgG ELISAs, 
these results may have had a sampling bias because not 
all serum samples tested by ELISA could be tested by 
IFA. This bias was, however, minimized, because the 
tested serum panel included 15/16 false-negative samples 
observed for the ELISAs.
The sensitivity of the selected molecular assays 
was found to be more modest (79.6% for qRT-PCR and 
83.3% for LCD array) than for serologic methods and 
to be associated with the patient country of origin. This 
result is consistent with the fi nding that the application of 
molecular assays in different settings is hampered by the 
high diversity of the CCHFV genomes, whereas serologic 
methods can have a broader use due to cross-reactivities. 
In particular, the qRT-PCR seems to be less sensitive for 
patients originating from the Balkans region and Turkey 
than for patients from other countries compared with in-
house reference molecular methods. The in-house methods 
developed by reference laboratories are optimized for 
detection of strains circulating in that area, which may 
result in a lower detection limit when compared with 
methods that cover a broader spectrum. However, other 
factors, such as RNA degradation due to freezing and 
thawing cycles or inhibition of PCR reactions because of 
inhibitory compounds in the samples, may have contributed 
to decreased sensitivity of molecular methods compared 
with serologic methods.
The observed specifi city was excellent for all assays, 
ranging from 95.5% to 100% when compared with the 
reference method and equal to 100% when compared 
with a composite reference standard. However, predictive 
positive and negative values for the different assays could 
not be calculated because precise prevalence data are not 
available for most CCHF-endemic areas, and these data 
cannot be predicted for areas where the virus could emerge.
The CCHF IFA demonstrated a higher complexity in 
equipment, technique, and interpretation. However, the 
interpretation of fl uorescence patterns may enable trained 
users to differentiate positive from cross-reactive serum 
samples, whereas such false positives may not be avoided 
with the ELISA. The operational characteristics of the 
molecular assays were comparable. Both methods required 
regular equipment maintenance and specifi c training 
for appropriate use of the equipment; however, this was 
more apparent for the real-time qRT-PCR method. The 
LCD array technique was considered to be complex but 
acceptable. Training for technique and result interpretation 
was recommended for each method.
All participating laboratories are reference centers 
for CCHF laboratory diagnosis and surveillance in 
their respective countries, and some are World Health 
Organization collaborating centers. The protocols from 
reference methods in use at each site have been extensively 
validated previously (16–20,24). In addition, the 
laboratories participated in a recent international external 
quality assessment (34). Therefore, local conditions at the 
participating sites and validity of reference methods were 
considered comparable.
The multicenter design of this study enabled the testing 
of a large sample size, representative of >1 population, so 
fi ndings could be more generally applicable. In addition, 
sample panels were constituted without any selection for 
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Table 5. Operational characteristics of selected CCHF diagnostic assays* 
Operational characteristic 
Mean score 
VectoCrimea-CHF 
ELISA†
Crimean-Congo 
Fever Mosaic 2 IFA‡ 
RealStar CCHFV 
RT-PCR Kit 1.2§ 
CCHF2006 1.5 LCD 
Kit (26)
Equipment¶
 Maintenance of equipment required 0.8 0.3 0.3 0.3
 Training for equipment required 0.8 0.7 0.3 0.5
 Additional equipment required 0.8 1.0 0.5 0.8
Technique 
 Clarity of instructions¶ 1.0 0.7 1.0 1.0
 Technical training required¶ 0.8 0.3 0.3 0.3
 Technical complexity# 2.0 1.7 1.5 1.3
Interpretation 
 Training required for result interpretation¶ 1.0 0.7 0.8 0.8
 Ease of interpretation of results# 1.5 1.3 1.5 1.5
Total score 8.5/10 6.7/10 6.0/10 6.3/10 
*CCHF, Crimean-Congo hemorrhagic fever; IFA, immunofluorescent assay; CCHFV, CCHF virus; RT-PCR, reverse transcription PCR; LCD, low-cost, 
low-density. 
†Vector-Best, Novosibirsk, Russia. 
‡Euroimmun, Luebeck, Germany. 
§Altona-Diagnostics, Hamburg, Germany. 
¶A score of 1 was attributed when instructions were sufficiently clear or when no specific training, no additional equipment, or no regular equipment 
maintenance were necessary. 
#Score was attributed according to the degree of simplicity of the technique or interpretation: 2 if it was considered easy, 1 if it was considered 
acceptable, and 0 if it was considered difficult. 
RESEARCH
disease severity, and negative controls included not only 
healthy patients but also patients who had a wide range 
of other conditions, thereby avoiding infl ated estimates of 
diagnostic accuracy.
Our study has some limitations. Because archived 
samples were used for the study, specimen quality 
could have been affected; however, statistical analysis 
demonstrated that sample storage time and temperature did 
not infl uence sensitivity. Also, the use of different sample 
panels for serologic and molecular testing did not enable 
calculation of the added value of combining the serologic 
and molecular CCHF diagnostic methods evaluated.
The results of this study give additional guidance 
on the type of CCHF diagnostic tools that could be used 
in different contexts. During a large outbreak, easily 
interpretable tests for simultaneous analysis of numerous 
samples, such as the ELISA and real-time qRT-PCR, might 
be considered useful tools to identify CCHF cases. Methods 
available in smaller format size and demonstrating a long 
shelf life, such as the IFA and LCD array, could be used to 
identify sporadic cases or to confi rm single cases as part of 
a larger outbreak.
This study demonstrates that effi cient, well-
characterized serologic and molecular assays and protocols 
are available for CCHF diagnosis. The on-site use of such 
assays by outbreak assistance laboratories would greatly 
diminish the risks posed by the handling, packaging, and 
shipping of highly infectious samples. Moreover, acquiring 
diagnostic reagents would be more time- and cost-effective 
for laboratories than would the organization of compliant 
packaging and shipment of hazardous biologic material 
to reference laboratories abroad. Nevertheless, laboratory 
personnel should receive the appropriate training to perform 
the different assays (e.g., during international workshops or 
network meetings). Collaborative evaluations of diagnostic 
methods remain essential to guide decision-making, 
especially with emerging diseases, where a standard is 
frequently missing, and laboratory expertise is rare.
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